Which Pre-Surgery combo works best for HER2+ breast cancer? new trial aims to find out
NCT ID NCT07220135
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing two standard chemotherapy combinations given before surgery for people with HER2-positive early breast cancer. One group gets docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP); the other gets the same without carboplatin (THP). The main goal is to see which regimen leads to a higher rate of complete tumor disappearance (pathologic complete response). About 100 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab
What this could lead to
If it works, this could help doctors choose the most effective pre-surgery drug combination for HER2-positive breast cancer, potentially improving outcomes.
What could go wrong
This is a small, early-phase study (100 participants) comparing already standard treatments, so it may not lead to a new approach. Side effects from chemotherapy can be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
KUCC - Briarcliff
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-••••
-
KUCC - Indian Creek
RECRUITINGOverland Park, Kansas, 66211, United States
Contact Phone: •••-•••-••••
-
KUCC - Lee's Summit
RECRUITINGLee's Summit, Missouri, 64064, United States
Contact Phone: •••-•••-••••
-
KUCC - Olathe
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-••••
-
KUCC - Overland Park
RECRUITINGOverland Park, Kansas, 66215, United States
Contact Phone: •••-•••-••••
-
The University of Kansas Cancer Center (KUCC)
RECRUITINGFairway, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Kansas Cancer Center - North
RECRUITINGKansas City, Missouri, 64154, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Kansas Cancer Center - Westwood
RECRUITINGKansas City, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••